Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. by Quaife, Matthew et al.
Post-tuberculosis mortality and morbidity: Valuing the hidden epidemic 
Matthew Quaife, Faculty of Public Health and Policy, and TB Modelling Group, TB Centre, London 
School of Hygiene and Tropical Medicine, London, UK 
Rein MGJ Houben, TB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, 
London, UK 
Brian Allwood, Division of Pulmonology, Department of Medicine, Stellenbosch University, South 
Africa 
Ted Cohen, Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New 
Haven, USA 
Anna K. Coussens, Infectious Diseases and Immune Defence Division, Walter and Eliza Hall Institute 
of Medical Research, Parkville, Australia 
Anthony D. Harries, Centre for Operational Research, International Union Against Tuberculosis and 
Lung Disease, Paris, France 
Sanne van Kampen, National eHealth Living Lab, Department of Public Health and Primary Care, 
Leiden University Medical Center, the Netherlands 
Florian Marx, DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), 
Faculty of Science & Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty 
of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa  
Sedona Sweeney, Faculty of Public Health and Policy, London School of Hygiene and Tropical 
Medicine, London, UK 
Robert S. Wallis, Aurum Institute, Johannesburg 
Nicolas A Menzies, Department of Global Health and Population, Harvard T H Chan School of Public 
Health, Boston, MA, USA 
  
Case fatality rates for tuberculosis disease (TB) have fallen progressively over the past 20 years, and 
an estimated 54 million people have survived TB since 2000.1 More recently there have been 
increasing efforts to understand the long-term implications of morbidity and mortality post-
tuberculosis, and a growing body of evidence describes how successful completion of treatment is 
unlikely to represent the end of ill health.2 
A recent meta-analysis estimated all-cause mortality to be 2.91 (95%CI: 2.21–3.84) times greater 
among individuals post-tuberculosis compared to age- and sex-matched controls.3 While these 
estimates may be inflated by coalescing factors predisposing to both TB and early mortality, 
separate lines of research have described the causal pathways through which TB impacts future 
health. These long-term post-tuberculosis sequelae include substantial morbidity from residual 
tissue damage, despite microbiologic cure. Evidence from meta-analysis suggests that pulmonary TB 
is an independent risk factor for airflow obstruction and spirometric restriction4, alongside chronic 
obstructive pulmonary disease (COPD)5. TB meningitis and musculoskeletal TB also cause substantial 
long-term morbidity, and individuals post-tuberculosis face elevated risks of recurrent TB.6  
However, chronic impairments are not yet reflected in conventional measures of TB burden7, or in 
analyses comparing TB policy options.8, 9 Here we describe how the burden of post-tuberculosis 
mortality and morbidity can be quantified using the disability-adjusted life year (DALY) framework. 
We provide an example of how this can change TB burden estimates in a high-incidence setting and 
consider the consequences for TB interventions, programming, and future research.   
DALYs are a composite measure of health loss widely used to evaluate the impact and cost-
effectiveness of health programmes. Interventions seek to avert DALYs, which are the sum of years 
of life lost due to premature death and years lived with disability.7 In a typical analysis, DALYs 
averted by TB interventions only account for the mortality and morbidity accruing during treatment 
of TB disease, assuming that survivors return to full health post-tuberculosis.9 Although some 
conditions have disability weights representing chronic disability following resolution of acute 
disease (e.g. long term consequences of stroke), TB does not.1 
As an example, we considered pulmonary TB in India and calculated conservative estimates based 
only on post-tuberculosis changes in COPD prevalence only (Figure 1). For active TB DALYs, we 
assumed a 2-year duration of disability and case fatality estimates reported by WHO.10 To calculate 
post-tuberculosis years of life lost, we estimated a lower-bound mortality rate ratio (MRR) of 1.22 
based on elevated COPD prevalence and mortality among post-tuberculosis individuals.5 For post-TB 
morbidity we estimated a post-tuberculosis disability weight of 0.053 based on elevated post-
tuberculosis COPD prevalence and published disability weights for COPD and other chronic 
respiratory diseases.  
We find that if post-tuberculosis mortality and morbidity is considered, the estimated burden of TB 
in India due to incident TB in 2018 increases by an additional 6.1 million DALYs, a 54% increase on 
estimates that assume a return to full health at the end of TB treatment. This burden would further 
increase, if post-tuberculosis conditions other than COPD were considered. We estimate an 
additional 20.1m DALYS (a 174% increase) as upper-bound, assuming that all excess mortality was 
attributable to past TB (MRR of 2.91)3. 
One implication of accounting for post-tuberculosis ill-health is a change in the prioritisation of TB 
programming. For example, the impact and cost-effectiveness of preventative interventions will 
increase due to greater DALYs averted per TB episode prevented – particularly relevant in the 
context of recent vaccine trials, and high-level political commitments to provide preventative 
therapy to 30 million individuals by 2022.11, 12 Interventions that limit lung damage from TB disease 
should also receive increased attention, including tools allowing earlier TB diagnosis 13, and new 
regimens that protect lung function during TB treatment.14 
Given this potentially large burden of disease associated with post-tuberculosis, several lines of 
future research are important. First, clinical evidence on post-tuberculosis points to a highly 
heterogeneous set of symptoms and conditions, which need to be understood to enable more 
tailored post-tuberculosis care. Second, there is little evidence on how mortality and morbidity 
exacerbate household and macro-economic consequences of TB, since current estimates assume no 
costs are incurred and no productivity is diminished after treatment. Third, consistent measurement 
of lung damage could be used to quantify whether case finding is diagnosing cases earlier in their 
disease, which in turn relates to preventing transmission.15 Fourth, estimates of mortality and 
morbidity from meta-analyses remain subject to bias due to confounding, and work is needed to 
confirm the causal impact of post-tuberculosis on long-term morbidity and mortality.  
While much remains unknown, post-tuberculosis morbidity and mortality are a significant part of TB 
natural history, which deserve greater integration into the END TB strategy. As TB policies focus on 
both care and prevention, research and policy makers cannot ignore the impact and needs of 
individuals after resolution of TB disease.12  
 
Figure 1: Demonstration of post-tuberculosis DALY loss for a typical survivor of pulmonary 
tuberculosis treatment in India without HIV infection. Shaded blue area does not consider 
mortality or morbidity from conditions which share common causes with tuberculosis, thus this 
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